Company Overview and News
KUALA LUMPUR (Aug 20): Based on corporate announcements and news flow today, companies in focus on Tuesday (Aug 21) may include the following: Utusan Melayu (Malaysia) Bhd, Petrol One Resources Bhd, Eita Resources Bhd, Gadang Holdings Bhd, Dayang Enterprise Holdings Bhd, Petronas Dagangan Bhd, Allianz Malaysia Bhd, United Plantations Bhd, Eastern and Oriental Bhd (E&O), Velesto Energy Bhd, Amway (Malaysia) Holdings Bhd and Rex Industry Bhd.
9261 UPBMF 5681 5141 7027 1163 2089 5754 5209 5208 9946 BSMAF 1818
KUALA LUMPUR (Aug 20): Practice Note 17 (PN17) entity Petrol One Resources Bhd said it has submitted an appeal to Bursa Malaysia Securities against the latter’s decision to delist its securities from the Main Market of the local bourse.
KUALA LUMPUR (Aug 13): The FBM KLCI is seen starting the week on a flat note and struggle to defend the 1,800-point level, tracking the weaker close at most global markets last Friday.
7223 7168 7027 0082 5246 9695 5025 5014 CIMDF 1023 5754 4995 7219 MYPRY
KUALA LUMPUR (Aug 10): Petrol One Resources Bhd, a Practice Note 17 (PN17) company, said today it is unable to implement the proposed regularisation plan by tomorrow (Aug 11), despite numerous extensions granted by Bursa Securities.
7027 BSMAF 1818
KUALA LUMPUR (Aug 10): Based on corporate announcements and news flow today, stocks in focus on Monday may include the following: Malaysia Smelting Corp Bhd, Westports Holdings Bhd, YFG Bhd, Marine & General Bhd, NWP Holdings Bhd, Minetech Resources Bhd, Green Packet Bhd, Malaysia Airports Holdings Bhd, PRG Holdings Bhd, CIMB Group Holdings Bhd, Utusan Melayu (Malaysia) Bhd, Versatile Creative Bhd, PLS Plantations Bhd, Petrol One Resources Bhd and Jadi Imaging Holdings Bhd.
7223 7168 7027 0082 5246 9695 7099 5025 5014 CIMDF 1023 5754 4995 7219 MYPRY
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...